Skip To Main Content
Určeno pro odbornou veřejnost
Campus
Campus
View Full Results

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Impact of Time-In-Range on Diabetes Management

Impact of Time-In-Range on Diabetes Management

Číst více
How does Dupixent help recover smell?

How does Dupixent help recover smell?

Číst více
How does Dupixent help recover smell?

How does Dupixent help recover smell?

Číst více
How does Dupixent help recover smell?

How does Dupixent help recover smell?

Číst více
How does Dupixent help recover smell?

How does Dupixent help recover smell?

Číst více
How does Dupixent help recover smell?

How does Dupixent help recover smell?

Číst více
How does Dupixent help recover smell?

How does Dupixent help recover smell?

Číst více
2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

Číst více
New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

Číst více
New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

Číst více
New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

Číst více
New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

Číst více